Carlos Danger, MD
Psychiatry · Miami, FLNPI 1508890153
Payments from drug & device makers
Across 423 payments — averaging $5172.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.1M
- Janssen Research & Development, LLC$932K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$100K
- Sage Therapeutics, LLC$11K
- Avanir Pharmaceuticals, Inc.$4K
- Teva Pharmaceuticals USA, Inc.$291
- plus $964 from 10 others
Across 5 payments — averaging $166.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$835
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 248 | $1,140,384 |
| Janssen Research & Development, LLC | 110 | $931,840 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $99,875 |
| Sage Therapeutics, LLC | 6 | $10,700 |
| Avanir Pharmaceuticals, Inc. | 2 | $3,788 |
| Teva Pharmaceuticals USA, Inc. | 13 | $291 |
| Lundbeck LLC | 9 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $198 |
| Otsuka America Pharmaceutical, Inc. | 6 | $116 |
| Indivior Inc. | 4 | $99 |
| Johnson & Johnson | 4 | $94 |
| Alkermes, Inc. | 4 | $80 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
How this compares
$2,187,842 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.